Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PARG | Q86W56 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24813004 | 0.82 | AKR1C3 (0.51) | L3MBTL1ALDH1A1MAPTHPGDTDP1 | |
| SCHEMBL30708130 | 0.82 | AKR1C3 (0.51) | L3MBTL1ALDH1A1MAPTHPGDTDP1 | |
| SCHEMBL17102824 | 0.79 | L3MBTL1 (0.70) | L3MBTL1ALDH1A1MAPTHPGDTDP1 | |
| SCHEMBL29331520 | 0.73 | RXRA (0.51) | ALDH1A1MAPTHPGDTDP1AKR1C3 | |
| SCHEMBL16727066 | 0.72 | L3MBTL1 (0.46) | L3MBTL1MAPTAKR1C3AKR1C2 | |
| SCHEMBL18075562 | 0.72 | IDO1 (0.50) | ALDH1A1MAPTHPGDTDP1KDM4E | |
| SCHEMBL30275137 | 0.72 | L3MBTL1 (0.72) | L3MBTL1ALDH1A1HPGDAKR1C3PTGDR2 | |
| SCHEMBL26683954 | 0.71 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1MAPTHPGDTDP1 | |
| SCHEMBL360344 | 0.71 | L3MBTL1 (0.76) | L3MBTL1ALDH1A1MAPTAKR1C3KDM4E | |
| SCHEMBL15747688 | 0.70 | L3MBTL1 (0.60) | L3MBTL1ALDH1A1MAPTHPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887890-B2 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1291341-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | MPL, THPO, TEK | L3MBTL1 1806/4885ALDH1A1 2042/4885MAPT 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.